{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:10:53Z","timestamp":1789143053669,"version":"build-2803163510"},"reference-count":15,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.medj.2026.101270","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:32:45Z","timestamp":1789140765000},"page":"101270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Generalized myasthenia gravis: Clinical trials to watch"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9549-2594","authenticated-orcid":false,"given":"Sarah","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5381-5995","authenticated-orcid":false,"given":"Paolo","family":"Doksani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"James F.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2026.101270_bib1","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.medj.2026.101270_bib2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40259-024-00701-1","article-title":"New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making","volume":"39","author":"Gerischer","year":"2025","journal-title":"BioDrugs"},{"key":"10.1016\/j.medj.2026.101270_bib3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/jnnp-2024-334404","article-title":"C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis","volume":"96","author":"Huntemann","year":"2025","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.medj.2026.101270_bib4","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMoa2501561","article-title":"A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis","volume":"392","author":"Nowak","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101270_bib5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1084\/jem.192.1.129","article-title":"BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population","volume":"192","author":"Thompson","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.medj.2026.101270_bib6","unstructured":"https:\/\/www.neurologylive.com\/view\/telitacicept-moves-forward-global-phase-3-study-generalized-myasthenia-gravis. (2025)."},{"key":"10.1016\/j.medj.2026.101270_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.msard.2018.10.006","article-title":"Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study","volume":"27","author":"Rejdak","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.medj.2026.101270_bib8","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101270_bib9","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/ene.14124","article-title":"Cladribine in myasthenia gravis: a pilot open-label study","volume":"27","author":"Rejdak","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.medj.2026.101270_bib10","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/s41591-025-04170-z","article-title":"BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial","volume":"32","author":"Fedak","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101270_bib11","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41591-025-04171-y","article-title":"BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"32","author":"Vu","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101270_bib12","unstructured":"https:\/\/ir.kyvernatx.com\/news-releases\/news-release-details\/kyverna-presents-longer-term-phase-2-data-miv-cel-generalized. (2026)."},{"key":"10.1016\/j.medj.2026.101270_bib13","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20251652","article-title":"T cell engagers emerge as a compelling therapeutic modality","volume":"223","author":"Baeuerle","year":"2026","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.medj.2026.101270_bib14","unstructured":"https:\/\/www.sec.gov\/Archives\/edgar\/data\/1739410\/000119312526084444\/d108429dex992.htm. (2025)."},{"key":"10.1016\/j.medj.2026.101270_bib15","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200436","article-title":"AChR Autoantibody Pathogenic Properties Are Heterogeneously Distributed and Undergo Temporal Changes Among Patients With Myasthenia Gravis","volume":"12","author":"Khani-Habibabadi","year":"2025","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026002734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026002734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:33:04Z","timestamp":1789140784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634026002734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666634026002734"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2026.101270","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Generalized myasthenia gravis: Clinical trials to watch","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2026.101270","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101270"}}